Jump to Content
HOME
BROWSE
SUBJECTS
CLINICAL RESOURCES
DRUG INFORMATION
EDUCATION AND TRAINING
PHARMACY PRACTICE
CAREER DEVELOPMENT
AJHP
DRUG INFORMATION
PROFESSIONAL DEVELOPMENT
Sign in
Sign up
SEARCH
Advanced Search
Help
Sign in
Sign up
HOME
BROWSE
SUBJECTS
CLINICAL RESOURCES
DRUG INFORMATION
EDUCATION AND TRAINING
PHARMACY PRACTICE
CAREER DEVELOPMENT
AJHP
DRUG INFORMATION
PROFESSIONAL DEVELOPMENT
SEARCH
Advanced Search
Help
Search
Table of Contents
Front Matter
Preliminary Material
Chapters
Chapter 1:
A New Type of Blockbuster: The Growth of Biologics
Chapter 2:
Déjà Vu or Something New?–Comparing the Generic and Biosimilar Experiences
Chapter 3:
Bugs and Drugs, and Yeast and Mice, and Chinese Hamsters
Chapter 4:
The $250 Billion Pyramid: Analytics in Biosimilarity Determination
Chapter 5:
The Global Biosimilars Experience
Chapter 6:
The American Biosimilar Experience: Red, White, and Possibly Interchangeable
Chapter 7:
Biosimilar Clinical Trial Requirements
Chapter 8:
Immunogenicity and Pharmacovigilance in the Biosimilar Era
Chapter 9:
The Patent Dance and the Exclusivity Shuffle
Chapter 10:
Defining Biosimilar Value and Other Seemingly Impossible Tasks
Chapter 11:
Biosimilar Formulary Management Strategies
Conclusion: Biosimilars 2023
Back Matter
Index
Chapter 9:
The Patent Dance and the Exclusivity Shuffle
in
Biosimilars & Biologics
Editor:
Steven Lucio
DOI:
https://doi.org/10.37573/9781585285815.009
Restricted access
Email this content
Share Link
Copy this link, or click below to email it to a friend
Email this content
or copy the link directly:
https://publications.ashp.org/abstract/book/9781585285815/ch009.xml
The link was not copied. Your current browser may not support copying via this button.
Link copied successfully
Copy link
Share on facebook
Share on linkedin
Share on twitter
[18.97.9.174]
18.97.9.174
Sign in to annotate
Close
Edit
Character limit
500
/500
Delete
Cancel
Save
@!
Character limit
500
/500
Cancel
Save
View Expanded
View Table
View Full Size
